Physicians' Academy for Cardiovascular Education

Managing potassium to optimize therapy in heart failure

10' education - Aug. 28, 2018 - Prof. Peter van der Meer, MD - Groningen, The Netherlands

Impressive results with transthyretin-stabilizer that reduces mortality and hospitalization in patients with transthyretin-related cardiomyopathy

3' education - Aug. 27, 2018 - Prof. Claudio Rapezzi, Bologna, Italy

HFpEF: from understanding the physiology to development of new treatments

10' education - May 27, 2018 - ESC Heart Failure 2018, Vienna - Carolyn Lam, MD - Singapore - Online CME

Understanding the mechanisms of SGLT2 inhibition in heart failure and diabetes

10' education - May 28, 2018 - ESC HF 2018 - Vienna, Austria - Prof. Naveed Sattar - Glasgow, UK

Atrial fibrillation & HFpEF: Novel device and therapeutic approaches

10' education - May 27, 2018 - ESC Heart Failure 2018, Vienna - Dipak Kotecha - Birmingham, UK - Online CME

New left ventricular assist device lowers stroke risk vs. gold standard

3' education - Mar. 9, 2018 - ACC 2018, Orlando, FL, USA - James Januzzi - Boston, MA, USA

There is hope for treatment of HFpEF

3' education - Nov. 24, 2017 - WCN congress, Amsterdam, The Netherlands - Prof. Carolyn Lam, MD - Singapore

Highly adhering to a plant-based diet is associated with a lower risk of developing HF

3' education - Nov. 14, 2017 - AHA 2017 - Anaheim, CA - AHA 2017 - Anaheim, CA, USA

Heart failure & Diabetes: Time for a more unified approach

10' education - Oct. 19, 2017 - Barcelona, Spain - Stefan D. Anker MD, Berlin, Germany - PACE-CME symposium held at ESC 2017

Step forward in telemonitoring through use of an algorithm that risk-stratifies HF patients

3' education - May 31, 2017 - ESC HF 2017, Paris

Disappointing results with therapy for acute heart failure

3' education - Apr. 30, 2017 - ESC HF 2017, Paris

Challenges in Heart Failure management: Diabetes and Renal Impairment

10' education - May 12, 2017 - Paris, France - Martin Cowie, MD - ESC Heart Failure, Paris

SGLT2 inhibition & Heart Failure: Lessons from EMPA REG Outcome

10' education - May 9, 2017 - Paris, France - Per-Henrik Groop, MD - ESC Heart Failure, Paris

New diabetes drugs and heart failure: What have we learnt?

10' education - May 6, 2017 - Paris, France - John McMurray, MD - ESC Heart Failure, Paris

New diabetes treatments with CV benefit: A changing role for the cardiologist

3' education - Apr. 19, 2017 - Robert J Chilton, MD (San Antonio, TX, USA)

HFpEF in older adults: TTR amyloid, under diagnosed and treatable?

3' education - Nov. 12, 2016 - New Orleans, LA, USA - Mathew S. Maurer, MD (New York, NY, USA)
##SCROLLER_ITEMS_FULL_TITLE##

Peak VO2 maintained in HF patients on IV iron therapy

3' education - Nov. 22, 2016 - AHA 2016 - Dirk Jan van Veldhuisen, MD (UMC Groningen, The Netherlands)
##SCROLLER_ITEMS_FULL_TITLE##

Iron deficiency in the new HF guidelines

3' education - Aug. 29, 2016 - Peter van der Meer, MD - University Medical Center Groningen, The Netherlands
##SCROLLER_ITEMS_FULL_TITLE##

Extra work of checking device data weekly does not translate into benefit for HF patient

3' education - Oct. 25, 2016 - ESC - 2016 Rome - Martin Cowie, MD - National Heart & Lung Institute, London, UK
##SCROLLER_ITEMS_FULL_TITLE##

Heart failure news at the ESC

10' education - Aug. 29, 2016 - ESC - 2016 Rome - Frank Ruschitzka, MD - University Heart Center, Zurich, Switzerland
##SCROLLER_ITEMS_FULL_TITLE##

Heart Failure news from ESC 2016 at a glance

3' education - Sep. 21, 2016 - ESC - 2016 Rome - Prof. Mariell Jessup (Philadelphia, PA, USA)

HF & Diabetes: SGLT2 inhibition a paradigm shift?

10' education - Aug. 29, 2016 - ESC 2016, Rome, Italy - John McMurray, MD University of Glasgow United Kingdom - Recorded at PACE-CME symposium held during ESC 2016 in Rome

The future of HF management: How does potassium binding fit within pharmacological treatment of heart failure?

10' education - June 28, 2016 - ESC HF 2016, Florence, Italy - Kenneth Dickstein, MD - University of Bergen Stavanger University Hospital, Norway

Heart failure and SGLT2 inhibition: understanding the mechanism for potential benefit

10' education - May 21, 2016 - ESC HF 2016, Florence, Italië - Naveed Sattar, MD - Glasgow Universtiy, Glasgow, UK

Hyperkalemia: Novel treatment strategies to manage potassium levels in heart failure

10' education - May 23, 2016 - ESC HF 2016, Florence, Italy - Peter van der Meer, MD - UMCG Groningen, The Netherlands

RAAS inhibition in heart failure: Corner stone of therapy & potassium homeostasis

10' education - May 23, 2016 - ESC HF 2016, Florence, Italy - Faiez Zannad, MD - CHU- Nancy University Nancy, France

SGLT2 inhibition and cardiovascular outcomes: lessons from recent clinical trials

10' education - May 21, 2016 - ESC HF 2016, Florence, Italy - David Fitchett, MD - University of Toronto, ONT, Canada

Current treatment of Diabetes in Heart Failure

10' education - May 21, 2016 - ESC HF 2016, Florence, Italy - Adriaan Voors, MD - UMCG Groningen, The Netherlands

Two additions to the therapeutic armory to treat HFrEF

3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Scott D. Solomon, MD - Boston, MA, USA

Managing cardiorenal syndrome in the context of heart failure

3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Peter A. McCullough, MD - Dallas, TX, USA

New ESC guidelines on management of CVD during pregnancy

News - Sep. 14, 2018

The new guidelines on management of CVD during pregnancy consider new evidence on diagnostic techniques, risk assessment and drug therapy that became available since the 2012 edition.

ESC debate | First-line therapies in HFrEF - ACE inhibitors or sacubitril/valsartan?

ESC 2018 - debates

ESC 2018 The benefit of sacubitril/valsartan in HFrEF is not subject to debate, but opinions do vary on when to use it. An impression of the arguments on whether or not it should be the starting treatment.

Managing potassium to optimize therapy in heart failure

10' education - Aug. 28, 2018 - Prof. Peter van der Meer, MD - Groningen, The Netherlands
Prof. Van der Meer describes the prevalence of hyperkalemia and its effects on the use of RAAS inhibition and discusses some potential novel potassium binders.

Prof. Van der Meer describes the prevalence of hyperkalemia and its effects on the use of RAAS inhibition and discusses some potential novel potassium binders.

Impressive results with transthyretin-stabilizer that reduces mortality and hospitalization in patients with transthyretin-related cardiomyopathy

3' education - Aug. 27, 2018 - Prof. Claudio Rapezzi, Bologna, Italy
In a randomized trial treatment with tafamidis resulted in impressive, significantly reduced mortality and hospitalization due to CV events in patients with ATTR-CM and HF.

ESC 2018 In a randomized trial treatment with tafamidis resulted in impressive, significant reduced mortality and hospitality due to CV events in patients with ATTR-CM and HF.

High prevalence of coronary microvascular dysfunction in patients with HFpEF

Literature - Sep. 10, 2018 - Shah SJ et al. - Eur Heart J 2018

Impaired coronary microvascular function is highly prevalent in HFpEF patients and is associated with high levels of natriuretic peptides, systemic endothelial dysfunction, and cardiac dysfunction.

ARNI can be initiated early and safely in hospitalized patients after acute HF episode

News - Sep. 3, 2018

ESC 2018 The TRANSITION study results show that sacubitril/valsartan was safe and well-tolerated in a wide range of HFrEF patients who have been stabilized after an acute HF episode , showing CV safety.

No benefit from direct anticoagulation for decompensated heart failure

News - Aug. 27, 2018

ESC 2018 In the COMMANDER-HF study, rivaroxaban did not significantly reduce CV mortality and morbidity in HFrEF patients with CAD with recent decompensation.

Cardiac factors may mediate the association between HF and cancer

Literature - Aug. 22, 2018 - Meijers WC, et al. - Circulation 2018

Studies in mice and humans suggest that heart failure is associated with enhanced tumor growth, independent of hemodynamic impairment, and may be caused by secretion of cardiac factors.

HFpEF: from understanding the physiology to development of new treatments

10' education - May 27, 2018 - ESC Heart Failure 2018, Vienna - Carolyn Lam, MD - Singapore - Online CME
Prof. Carolyn Lam recognizes six mechanisms that play a role in the pathophysiology of HFpEF. She shares evidence why these mechanisms may be targeted for therapy.

Prof. Carolyn Lam recognizes six mechanisms that play a role in the pathophysiology of HFpEF. She shares evidence why these mechanisms may be targeted for therapy.

ARNI provided no additional benefit on renal function compared with ARB

Literature - Aug. 7, 2018 - Haynes R et al. - Circulation 2018; published online ahead of print

In patients with chronic kidney disease, sacubitril/valsartan had similar effects on renal function compared with irbesartan after 12 months of therapy. ARNI therapy did lower BP, NT-proBNP and troponin.

Meeting Impression | Contemporary management of a patient with heart failure and diabetes: Implications from recent trials

May 28, 2018 – Vienna, Austria
May 28, 2018 – Vienna, Austria

Download the meeting impression of this PACE symposium during Heart Failure 2018, which considered what recent outcome trials with glucose-lowering trials can tell us about us about optimal management of patients with HF and diabetes.

Summary | Understanding the mechanisms of SGLT2 inhibition in heart failure and diabetes

Vienna, Austria - May 28, 2018

Prof. Sattar looked at the data of recent outcome trials to postulate how they might work to exert the observed clinical benefit. Altered hemodynamics likely importantly contribute to the benefits on HF outcomes.